New Mouse Model for Breast Cancer with Δ16HER2
Author Information
Author(s): Marchini Cristina, Gabrielli Federico, Iezzi Manuela, Zenobi Santa, Montani Maura, Pietrella Lucia, Kalogris Cristina, Rossini Anna, Ciravolo Valentina, Castagnoli Lorenzo, Tagliabue Elda, Pupa Serenella M., Musiani Piero, Monaci Paolo, Menard Sylvie, Amici Augusto
Primary Institution: Department of Bioscience and Biotechnology, University of Camerino, Camerino, Italy
Hypothesis
The Δ16HER2 splice variant promotes rapid tumor onset in mammary epithelium.
Conclusion
The study demonstrates that the Δ16HER2 splice variant can transform mammary epithelium in vivo, leading to aggressive tumor development.
Supporting Evidence
- All transgenic females developed multifocal mammary tumors with an average latency of 15.11 weeks.
- Immunohistochemical analysis confirmed the expression of Δ16HER2 in tumor tissues.
- Transgenic mice showed a high incidence of aggressive tumors and lung metastases.
Takeaway
Scientists created a special mouse that gets breast cancer quickly because of a specific gene change, helping us understand how some cancers grow.
Methodology
Transgenic mice expressing Δ16HER2 and luciferase were generated and monitored for tumor development.
Limitations
The study primarily focuses on a specific mouse model, which may not fully represent human breast cancer complexities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website